A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing–remitting multiple sclerosis

Background: Mycophenolate mofetil (MMF, CellCept®) has been utilized as an antirejection agent in transplant recipients and in patients with myriad autoimmune disorders including multiple sclerosis (MS). Objective: To investigate radiographic and clinical safety involving monotherapy use of daily or...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Frohman, Elliot M., Cutter, Gary, Remington, Gina, Gao, Hongjiang, Rossman, Howard, Weinstock-Guttman, Bianca, Durfee, Jacqueline E., Conger, Amy, Carl, Ellen, Treadaway, Katherine, Lindzen, Eric, Salter, Amber, Frohman, Teresa C., Shah, Anjali, Bates, Angela, Cox, Jennifer L., Dwyer, Michael G., Stüve, Olaf, Greenberg, Benjamin M., Racke, Michael K., Zivadinov, Robert
פורמט: Artigo
שפה:Inglês
יצא לאור: SAGE Publications 2010
נושאים:
Original Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3002613/
https://ncbi.nlm.nih.gov/pubmed/21180633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285609353354
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים